TORONTO, Oct. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its partner, Amarin Corporation plc (NASDAQ: AMRN) announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress ("CCC") in Quebec City, from October 23 to 26, 2025. These presentations reflect the continued commitment of HLS and Amarin to advancing the broader therapeutic potential of Icosapent Ethyl ("IPE") and Eicosapentaenoic Acid ("EPA"), further highlighting their dedication to improving cardiovascular care for appropriate at-risk patients.
Read more at newswire.caHLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.